About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Ferring B.V. v. Watson Laboratories, Inc. (I) (Fed. Cir. 2014) | Main | Webinar on Prosecution and Diligence Strategies »

August 29, 2014

Business of Biosimilars Conference

Boston SkylineThe Institute for International Research (IIR) will be holding its 15th Annual Business of Biosimilars conference from October 20-22, 2014 in Boston, MA.  The conference will offer presentations on the following topics:

Pre-Conference Day -- October 20:

• Around the World in 1 Day: Emerging Markets Pre-Conference Summit
• Women Leaders in Pharma Dinner

Main Conference Day One -- October 21:

• The Continuing Shakedown of Biosimilar Developers
• Looking at the Commercial Realities of the Biosimilar Market (panel)
• Business Opportunities in the US Market
• Understanding the Global Payer & Reimbursement Landscape
• Global Harmonization of Biosimilar Regulatory Pathways
• Takeaways on High Profile Court Cases (panel)
• Legal and IP Landscape for 2014 and Beyond
• News from the EU over the past 12 Months: Any Changes in European Biosimilar Guidelines, Approvals, and Perceptions?
• From the First European Biosimilar Epoetin Alfa Product to Third Wave Biosimilars — Experience Gained From Establishing Successful Development Organizations for Global Quality Biosimilars (case study)
• Partnership Spotlight: Penetrating Emerging Markets Hand in Hand (case study)

Main Conference Day Two -- October 22:

• Expert Opinions: Biosimilar Policies & Adoption (panel)
• Hit the Nail on the Head: Creating an Optimal Development Plan (case study)
• Alternatives to the "Abbreviated" Biosimilar Pathway: Full Applications in Biobetters
• "How to Play": Commercialization Strategy to Maximize Uptake and Market Potential

IIRThe agenda for the conference can be found here.  A complete brochure for this conference, including an agenda, list of speakers, descriptions of the scheduled presentations, and registration information can be downloaded here.

The registration fee for this conference is $2,295 (conference only) or $2,895 (conference and workshop).  Those registering before September 12, 2014 will receive a $200 discount.  Those interested in registering for the conference can do so here.

Patent Docs is a media partner of the Business of Biosimilars conference.

Posted at 10:13 PM in Conferences & CLE's |

Comments

The comments to this entry are closed.

November 2023

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30    

Categories

Archives

More...